Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

25.11 USD +1.89 (+8.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,409,450
Open 23.40
Bid (Size) 25.08 (1)
Ask (Size) 25.15 (5)
Prev. Close 23.22
Today's Range 23.08 - 25.17
52wk Range 18.18 - 27.80
Shares Outstanding 313,387,205
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial,... 
From Business Wire News Releases
Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
Exelixis, Inc. (Nasdaq: EXEL) and GamaMabs Pharma SA today announced that they have entered into an agreement under which Exelixis will, upon the future closing of the asset purchase and subject to... 
From Business Wire News Releases

Performance

YTD
+22.31%
+22.31%
1 Month
+7.49%
+7.49%
3 Month
+5.46%
+5.46%
6 Month
+19.57%
+19.57%
1 Year
-3.42%
-3.42%

More News

Read More
Bristol Myers Squibb Reports First Quarter Financial Results for 2021
From Business Wire News Releases
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
From Business Wire News Releases
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
From Business Wire News Releases
Exelixis: Q1 Earnings Insights
Tags EXEL Market News Earnings
From Benzinga
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors
From Business Wire News Releases
Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma?
Tags PFE RPRX AZN
From Motley Fool
Analysts Forecast 22% Upside For The Holdings of FBT
Tags ETFs
From ETF Channel
Exelixis Inc (EXEL) Q1 2021 Earnings Call Transcript
Tags Market News EXEL
From Motley Fool
The Smartest Stocks to Buy With $50 Right Now
Tags SKLZ GRWG EXEL
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.